313 related articles for article (PubMed ID: 26846107)
1. The clinical and prognostic significance of CD14(+)HLA-DR(-/low) myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy.
Wang D; An G; Xie S; Yao Y; Feng G
Tumour Biol; 2016 Aug; 37(8):10427-33. PubMed ID: 26846107
[TBL] [Abstract][Full Text] [Related]
2. Increase in CD14+HLA-DR -/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis.
Arihara F; Mizukoshi E; Kitahara M; Takata Y; Arai K; Yamashita T; Nakamoto Y; Kaneko S
Cancer Immunol Immunother; 2013 Aug; 62(8):1421-30. PubMed ID: 23764929
[TBL] [Abstract][Full Text] [Related]
3. Increased circulating CD14(+)HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer.
Tian T; Gu X; Zhang B; Liu Y; Yuan C; Shao L; Guo Y; Fan K
Cancer Biomark; 2015; 15(4):425-32. PubMed ID: 25792471
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic significance of CD14 (+) HLA-DR (-/low) myeloid-derived suppressor cells in patients with hepatocellular carcinoma received transarterial radioembolization with Yttrium-90.
Boral B; Ballı HT; Sözütok S; Pehlivan UA; Aikimbaev K
Scand J Immunol; 2022 Mar; 95(3):e13132. PubMed ID: 34936119
[TBL] [Abstract][Full Text] [Related]
5. Frequency and Implications of myeloid-derived suppressor cells and lymphocyte subsets in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma.
Hetta HF; Zahran AM; Mansor SG; Abdel-Malek MO; Mekky MA; Abbas WA
J Med Virol; 2019 Jul; 91(7):1319-1328. PubMed ID: 30761547
[TBL] [Abstract][Full Text] [Related]
6. Circulating CD14
Gao XH; Tian L; Wu J; Ma XL; Zhang CY; Zhou Y; Sun YF; Hu B; Qiu SJ; Zhou J; Fan J; Guo W; Yang XR
Hepatol Res; 2017 Sep; 47(10):1061-1071. PubMed ID: 27764536
[TBL] [Abstract][Full Text] [Related]
7. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
[TBL] [Abstract][Full Text] [Related]
8. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
[TBL] [Abstract][Full Text] [Related]
9. High numbers of myeloid derived suppressor cells in peripheral blood and ascitic fluid of cirrhotic and HCC patients.
Elwan N; Salem ML; Kobtan A; El-Kalla F; Mansour L; Yousef M; Al-Sabbagh A; Zidan AA; Abd-Elsalam S
Immunol Invest; 2018 Feb; 47(2):169-180. PubMed ID: 29182438
[TBL] [Abstract][Full Text] [Related]
10. Myeloid-derived suppressor cells correlate with patient outcomes in hepatic arterial infusion chemotherapy for hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Terashima T; Kitahara M; Nakagawa H; Iida N; Fushimi K; Kaneko S
Cancer Immunol Immunother; 2016 Jun; 65(6):715-25. PubMed ID: 27083166
[TBL] [Abstract][Full Text] [Related]
11. Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells.
Deng Y; Cheng J; Fu B; Liu W; Chen G; Zhang Q; Yang Y
Oncogene; 2017 Feb; 36(8):1090-1101. PubMed ID: 27593937
[TBL] [Abstract][Full Text] [Related]
12. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
13. Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy.
Zhou J; Liu M; Sun H; Feng Y; Xu L; Chan AWH; Tong JH; Wong J; Chong CCN; Lai PBS; Wang HK; Tsang SW; Goodwin T; Liu R; Huang L; Chen Z; Sung JJ; Chow KL; To KF; Cheng AS
Gut; 2018 May; 67(5):931-944. PubMed ID: 28939663
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.
Mizukoshi E; Yamashita T; Arai K; Sunagozaka H; Ueda T; Arihara F; Kagaya T; Yamashita T; Fushimi K; Kaneko S
Hepatology; 2013 Apr; 57(4):1448-57. PubMed ID: 23174905
[TBL] [Abstract][Full Text] [Related]
15. Elevated frequencies of CD14
Xue G; Jiang M; Zhao R; Le A; Li J
Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
[TBL] [Abstract][Full Text] [Related]
16. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
17. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
Huang H; Zhang G; Li G; Ma H; Zhang X
Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
[TBL] [Abstract][Full Text] [Related]
18. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
[TBL] [Abstract][Full Text] [Related]
19. Interactions between interleukin-6 and myeloid-derived suppressor cells drive the chemoresistant phenotype of hepatocellular cancer.
Xu M; Zhao Z; Song J; Lan X; Lu S; Chen M; Wang Z; Chen W; Fan X; Wu F; Chen L; Tu J; Ji J
Exp Cell Res; 2017 Feb; 351(2):142-149. PubMed ID: 28109867
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
